Tumor markers for ovarian cancer: a comparative immunohistochemical and immunocytochemical study of two commercial monoclonal antibodies (OV632 and OC125)

A comparative immunohistologic and immunocytologic study was performed to assess the immunoreactivity of the monoclonal antibodies OC125 and OV632, both directed at antigens present on epithelial ovarian tumors. OC125 reacted with 53 of 59 ovarian carcinomas, 20 of 20 uterine carcinomas, and 25 of 1...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of clinical pathology Vol. 90; no. 4; pp. 391 - 396
Main Authors KOELMA, I. A, NAP, M, VAN STEENIS, G. J, JAN FLEUREN, G
Format Journal Article
LanguageEnglish
Published Chicago, IL American Society of Clinical Pathologists 01.10.1988
Subjects
Antibodies, Monoclonal
Antibody Specificity
Antigen-Antibody Reactions
Ascitic Fluid - analysis
Ascitic Fluid - pathology
Biological and medical sciences
Biomarkers, Tumor
Female
Female genital diseases
Gynecology. Andrology. Obstetrics
Humans
Immunohistochemistry - methods
Medical sciences
Ovarian Neoplasms - analysis
Ovarian Neoplasms - pathology
Staining and Labeling - methods
Tumors
Human
Immunohistochemistry
Ovarian diseases
Ovary
Carcinoma
Immunocytochemistry
Tumor
Tumoral marker
Monoclonal antibody
Malignant tumor
Woman
Female genital diseases
Online AccessGet full text

Cover

More Information
Summary:A comparative immunohistologic and immunocytologic study was performed to assess the immunoreactivity of the monoclonal antibodies OC125 and OV632, both directed at antigens present on epithelial ovarian tumors. OC125 reacted with 53 of 59 ovarian carcinomas, 20 of 20 uterine carcinomas, and 25 of 111 nongynecologic tumors (including 20 of 38 breast carcinomas). OV632 was demonstrated in 47 of 59 ovarian carcinomas, 11 of 20 uterine carcinomas, and only 7 of 111 nongynecologic tumors. With OV632 no reactivity was found in carcinomas of the breast or the gastrointestinal tract. Cytologic preparations of malignant effusions of patients with ovarian cancer showed reactivity with OC125 in 32 of 35 cases, and OV632 with positivity in 34 of 35 cases. Mesothelial cells in reactive effusions were OC125 positive in 16 of 20 cases but never showed positivity with OV632. The authors conclude that for histopathology a combination of OC125 and OV632 offers high sensitivity (0.86) and specificity (0.89) for ovarian cancer. For cytology, OV632 is the most specific tumor marker available.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0002-9173
1943-7722
DOI:10.1093/ajcp/90.4.391